Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer

January 7, 2024
By Sarah Donahue, MPH, NP
Commentary
Video

Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.

Managing nausea related to treatment with trastuzumab deruxtecan (T-DXd; Enhertu) for patients with hormone receptor–positive breast cancer is important to reducing fatigue and improve quality of life, according to Sarah Donahue, MPH, NP.

Donahue, a nurse practitioner at University of California, San Francisco, and part of the Oncology Nursing Society, spoke with CancerNetwork® about her strategies for mitigating the effects of nausea among patients at her practice. According to Donahue, she uses pre-medications such as doxorubicin and cyclophosphamide as well as other agents including olanzapine to the limit the amount of nausea that may follow treatment with T-DXd.

Transcript:

With T-DXd, many of my patients with hormone receptor–positive, HER2-negative or HER2-low metastatic breast cancer would qualify for this, and many of them have never had a medication, like T-DXd before. T-DXd can cause cardiovascular effects.

The other main [adverse] effect of that medication is mostly nausea. It’s pretty common. You’re giving a lot of pre-medications. You’re giving doxorubicin and cyclophosphamide; you’re giving them the works. And then you’re making sure that at home they have the antiemetics to use as needed. Sometimes, in the first cycle, I’ll help patients schedule it because it’s harder to catch up with the pain. I don’t want to create a situation where every time they’re coming in, they’re thinking about the nausea that they had last time, [feeling] worried, and having that anticipatory nausea, as well. I give them a lot of these medications to take at home with a little bit of scheduling.

What I found is that some of these patients will have a nausea that occurs for longer than you would expect with a medication. What I find is adding on olanzapine at bedtime for the first 3 to 5 nights starting the night of treatment really helps. Sometimes I have patients who just continue with that even longer or take it as needed, and they are needing it later on. When we’re talking about the patient’s quality of life, if they’re not eating well and they’re nauseated, they’re going to have some level of fatigue, low blood sugar, and lack of hydration because they’re not feeling well enough to drink. A lot of my goals to make them feel as normal as possible and having the least amount of fatigue so that they can do what they want to be doing—which makes them feel better emotionally, too—are really targeting that nausea and making sure that it is very well controlled.

Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
Advertisement

AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

Sabrina Serani
May 23rd 2025
Article

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer

Caroline Seymour
May 22nd 2025
Article

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

ONCOLOGY Staff
May 21st 2025
Article

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.


55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

Natalie Garver;Valerie L. Staradub, MD;Christopher Verdone;Kelly Mackessy;Alexandra Haraczy;Lianteng Zhi
May 20th 2025
Article
Related Content
Advertisement

AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists

Sabrina Serani
May 23rd 2025
Article

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer

Caroline Seymour
May 22nd 2025
Article

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

ONCOLOGY Staff
May 21st 2025
Article

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.


55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

Natalie Garver;Valerie L. Staradub, MD;Christopher Verdone;Kelly Mackessy;Alexandra Haraczy;Lianteng Zhi
May 20th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.